Xeris Biopharma Holdings, Inc. (XERS) Q1 FY25 Earnings Call

Q1 FY25 results, source: company transcript and SEC filings
QuarterQ1 FY25
Length29 minutes
EPS$-0.06
EPS consensus$-0.07

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY26

All XERS earnings ยท Back to XERS overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.